Norway Plasmid Dna Contract Manufacturing Market Size & Outlook
- HC Outsourcing
- CMO/CDMO
- Plasmid DNA Contract Manufacturing Market Outlook
- CMO/CDMO
Norway Plasmid Dna Contract Manufacturing Market, 2018-2030 (US$M)
Global Market
Related Markets
Ask a question about the plasmid dna contract manufacturing market
Norway plasmid dna contract manufacturing market highlights
- The Norway plasmid dna contract manufacturing market generated a revenue of USD 0.8 million in 2023 and is expected to reach USD 2.7 million by 2030.
- The Norway market is expected to grow at a CAGR of 18.6% from 2024 to 2030.
- In terms of segment, cell & gene therapy was the largest revenue generating application in 2023.
- Cell & Gene Therapy is the most lucrative application segment registering the fastest growth during the forecast period.
Plasmid dna contract manufacturing market data book summary
| Market revenue in 2023 | USD 0.8 million |
| Market revenue in 2030 | USD 2.7 million |
| Growth rate | 18.6% (CAGR from 2023 to 2030) |
| Largest segment | Cell & gene therapy |
| Fastest growing segment | Cell & Gene Therapy |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Cell & Gene Therapy, Immunotherapy |
| Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
Other key industry trends
- In terms of revenue, Norway accounted for 0.2% of the global plasmid dna contract manufacturing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK plasmid dna contract manufacturing market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 56.9 million by 2030.
The growing popularity of gene therapy and rising burden of cancer cases are the primary factors driving growth of the market in the region. Cancer is the second-leading cause of deaths globally with 19.3 million new cases and 10.0 million cancer deaths in 2020.
In Norway, where breast cancer is still the most prevalent type of cancer, followed by colorectal cancer and lung cancer, women comprised 46.0% of all new cases. The incidence of cancer cases and age-standardized incidence rates for majority of malignancies are rising, according to the most recent report from the Cancer Registry of Norway.
This pattern predicts that Norway's already significant cancer burden would continue to rise, putting more strain on the healthcare system in terms of screening & treatment. This would increase the demand for therapies further driving pDNA contract manufacturing market.
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Plasmid DNA Contract Manufacturing Market Scope
Plasmid DNA Contract Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Charles River Laboratories International Inc | View profile | 21,400 | 251 Ballardvale Street, Wilmington, MA, United States, 01887 | www.criver.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| TriLink BioTechnologies | View profile | 251-500 | San Diego, California, United States, North America | www.trilinkbiotech.com/ |
| BioCina | View profile | 101-250 | Thebarton, South Australia, Australia, Oceania | www.biocina.com/ |
| Viva Biotech | View profile | 1001-5000 | Shanghai, Shanghai, China, Asia | www.vivabiotech.com.cn/ |
| VGXI | View profile | 101-250 | The Woodlands, Texas, United States, North America | vgxii.com/ |
| PlasmidFactory | View profile | 11-50 | Bielefeld, Nordrhein-Westfalen, Germany, Europe | plasmidfactory.com/ |
| Esco Aster | View profile | 11-50 | Singapore, Central Region, Singapore, Asia | escoaster.com |
Norway Plasmid DNA Contract Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Plasmid DNA Contract Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Cell & Gene Therapy was the largest segment with a revenue share of 62.5% in 2023.
Horizon Databook has segmented the Norway plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The growing popularity of gene therapy and rising burden of cancer cases are the primary factors driving growth of the market in the region. Cancer is the second-leading cause of deaths globally with 19.3 million new cases and 10.0 million cancer deaths in 2020.
In Norway, where breast cancer is still the most prevalent type of cancer, followed by colorectal cancer and lung cancer, women comprised 46.0% of all new cases. The incidence of cancer cases and age-standardized incidence rates for majority of malignancies are rising, according to the most recent report from the Cancer Registry of Norway.
This pattern predicts that Norway's already significant cancer burden would continue to rise, putting more strain on the healthcare system in terms of screening & treatment. This would increase the demand for therapies further driving pDNA contract manufacturing market.
- Norway Plasmid Dna Contract Manufacturing Market Application Outlook (Revenue, USD Million , 2018-2030)
- Cell & Gene Therapy
- Immunotherapy
- Others
- Norway Plasmid Dna Contract Manufacturing Market Therapeutic Area Outlook (Revenue, USD Million , 2018-2030)
- Cancer
- Infectious Diseases
- Autoimmune Diseases
- Cardiovascular Diseases
- Others
- Norway Plasmid Dna Contract Manufacturing Market End User Outlook (Revenue, USD Million , 2018-2030)
- Pharmaceutical and Biotechnology Companies
- Research Institutes
Reasons to subscribe to Plasmid DNA Contract Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Plasmid DNA Contract Manufacturing Market Outlook databook
- Our clientele includes a mix of Plasmid DNA Contract Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway Plasmid DNA Contract Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Norway Plasmid DNA Contract Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Norway Plasmid Dna Contract Manufacturing Market, 2018-2030 (US$M)
Norway plasmid dna contract manufacturing market statistics, by application, 2018-2030 (US$M)
